ORPHA:213726
Serous carcinoma of the corpus uteri
Also known as: Endometrial serous carcinoma
Publications
444
79.6th percentile
Trials
2
Interventional, condition-specific
Researchers
1,065
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare high-grade endometrial carcinoma characterized by diffuse, marked nuclear pleomorphism, typically exhibiting complex papillary and/or glandular growth patterns and showing abnormal p53 and diffuse p16 immunohistochemistry. The tumor typically arises in atrophic endometrium or in an endometrial polyp. Most patients present with postmenopausal bleeding. Extrauterine metastasis is present in 40-50% of surgically staged cases, most frequently involving lymph nodes or peritoneal sites and omentum. Patients with extrauterine spread have poor outcomes, while endometrium-limited carcinoma has a better prognosis.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016268
- UMLS:C5679804
Additional Mondo synonyms (2)
body of uterus papillary carcinoma · endometrial capillary carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
444 matched papers (362 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
444
444 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
444 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
362 in the last 10 years · high confidence · 79.6th percentile (publications denominator)
Phrase hits: 444 · MeSH hits: 0
Who's working on it?
1,065
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Buza N10 papers · 2026
Department of Pathology, Yale University School of Medicine, New Haven, CT, 06520-8023.
Papers in Europe PMC - 02Burandt E9 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Papers in Europe PMC - 03Fraune C9 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Papers in Europe PMC - 04Hube-Magg C9 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Papers in Europe PMC - 05Hui P9 papers · 2026
Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
Papers in Europe PMC - 06Krech T9 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Papers in Europe PMC - 07Sauter G9 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Papers in Europe PMC - 08Simon R9 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Papers in Europe PMC - 09Steurer S9 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Papers in Europe PMC - 10Bernreuther C8 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 11 September 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
high confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05256225·RECRUITING·Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Not reviewed·Conditions: Endometrial Carcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma·Matched via name phrase
- NCT04716686·RECRUITING·Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Not reviewed·Conditions: Endometrial Carcinoma · Serous Carcinoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 11 · after dedupe 11 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 11 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (11)
- isrctn·ISRCTN14643179·Recruiting·Assessing if stopping and starting standard of care medication for later stage melanoma can reduce the body's resistance to the treatment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10490346·No longer recruiting·An investigation of whether rucaparib is safe and more effective when combined with either one or two immunotherapy drugs (nivolumab and ipilimumab), when compared to rucaparib on its own
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11659025·No longer recruiting·PORTEC-4a: Randomised trial of standard or molecular profile-based recommendation for radiotherapy after surgery for women with early stage endometrial cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16426935·No longer recruiting·OCTOPUS - ovarian cancer trials of weekly paclitaxel
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15903698·Stopped·A Phase I/Ib Trial of the Oral Hedgehog inhibitor, LY2940680, in Combination with Weekly Paclitaxel in Patients with Platinum-Resistant, Recurrent Ovarian Cancer or Recurrent, Advanced, Solid Tumours.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN50772895·No longer recruiting·A study of Nintedanib compared to chemotherapy in patients with recurrent Clear Cell Carcinoma of the ovary or endometrium
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN84527805·No longer recruiting·Diagnostic accuracy of MRI, diffusion-weighted MRI, FDGPET/CT and Fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10356387·No longer recruiting·ICON8 Trials Programme
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14387080·No longer recruiting·Randomised phase III trial comparing concurrent chemoradiation and adjuvant chemotherapy with pelvic radiation alone in high risk and advanced stage endometrial carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16228756·No longer recruiting·PORTEC-2: Post-Operative Radiation Therapy for Endometrial Carcinoma - a multicentre randomised phase III trial comparing external beam radiation and vaginal brachytherapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16571884·No longer recruiting·A randomised trial of lymphadenectomy and of adjuvant external beam radiotherapy in endometrial cancer
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Serous carcinoma of the corpus uteri — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Serous carcinoma of the corpus uteri" OR "Serous carcinoma of corpus uteri" OR "Endometrial serous carcinoma" OR "body of uterus papillary carcinoma" OR "body of the uterus papillary carcinoma" OR "endometrial capillary carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Serous carcinoma of the corpus uteri" OR "Serous carcinoma of corpus uteri" OR "Endometrial serous carcinoma" OR "body of uterus papillary carcinoma" OR "body of the uterus papillary carcinoma" OR "endometrial capillary carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:36:53.104Z